HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

Abstract
We have recently identified targetable mutations in CSF3R (GCSFR) in 60% of chronic neutrophilic leukemia (CNL) and atypical (BCR-ABL-negative) chronic myeloid leukemia (aCML) patients. Here we demonstrate that the most prevalent, activating mutation, CSF3R T618I, is sufficient to drive a lethal myeloproliferative disorder in a murine bone marrow transplantation model. Mice transplanted with CSF3R T618I-expressing hematopoietic cells developed a myeloproliferative disorder characterized by overproduction of granulocytes and granulocytic infiltration of the spleen and liver, which was uniformly fatal. Treatment with the JAK1/2 inhibitor ruxolitinib lowered the white blood count and reduced spleen weight. This demonstrates that activating mutations in CSF3R are sufficient to drive a myeloproliferative disorder resembling aCML and CNL that is sensitive to pharmacologic JAK inhibition. This murine model is an excellent tool for the further study of neutrophilic myeloproliferative neoplasms and implicates the clinical use of JAK inhibitors for this disease.
AuthorsAngela G Fleischman, Julia E Maxson, Samuel B Luty, Anupriya Agarwal, Lacey R Royer, Melissa L Abel, Jason D MacManiman, Marc M Loriaux, Brian J Druker, Jeffrey W Tyner
JournalBlood (Blood) Vol. 122 Issue 22 Pg. 3628-31 (Nov 21 2013) ISSN: 1528-0020 [Electronic] United States
PMID24081659 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • CSF3R protein, human
  • Nitriles
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • Receptors, Colony-Stimulating Factor
  • ruxolitinib
  • Janus Kinases
Topics
  • Animals
  • Bone Marrow Transplantation
  • Disease Models, Animal
  • Granulocytes (pathology)
  • Humans
  • Janus Kinases (antagonists & inhibitors)
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (drug therapy, genetics)
  • Leukemia, Neutrophilic, Chronic (drug therapy, genetics)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Transgenic
  • Myeloproliferative Disorders (drug therapy, genetics, pathology)
  • Neutrophils (pathology)
  • Nitriles
  • Point Mutation
  • Protein Kinase Inhibitors (therapeutic use)
  • Pyrazoles (therapeutic use)
  • Pyrimidines
  • Receptors, Colony-Stimulating Factor (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: